沈海法

来自国立浙江大学维基
跳转至: 导航搜索

沈海法 Haifa Shen, Ph.D.
沈海法教授于1985年获浙江大学药学院药学学士学位,1997年获休斯顿德克萨斯大学博士学位,2001年在美国国家癌症研究中心完成博士后研究后进入Lexicon Pharmaceuticals公司担任药物研发科学家,2010年回到德克萨斯大学休斯顿医学院担任助理教授。目前,沈海法教授是美国康奈尔大学威尔康奈尔医学院细胞与发育生物学系教授,休斯顿卫理公会研究所纳米医学系研究员。沈海法教授一直致力于将纳米技术应用于肿瘤治疗学的发展,在Nature, NatureBiotechnology, Nature Genetics, Blood, Leukemia, Chemical Society Reviews, ACSNano, 和 Nano Letters, PNAS等顶级国际期刊上发表论文90余篇。作为美国国家癌症研究中心(RO1),美国国防部(DOD)癌症研究中心(U54)等机构的首席研究员/联合研究员,沈海法教授获得的基金资助近5000万美元。

Haifa Shen, Ph.D.
Professor of Nanomedicine
Weill Cornell Medical College

Dr. Shen graduated from Zhejiang Medical University in 1985, and obtained his PhD degree in 1997 from The University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his post-doctoral training at the National Cancer Institute in Maryland from 1997 to 2001. He joined the pharmaceutical industry thereafter, and worked on cancer drug development for 8 years. Dr. Shen came by to academia in early 2010 as an assistant professor in The University of Texas-Houston Medical School before joining Houston Methodist Research Institute in October, 2010.
Research in Dr. Shen’s laboratory is focused on development of novel therapeutics for cancer treatment. His laboratory has developed nanoporous silicon-based technology platforms for tumor tissue-specific delivery of cancer therapeutics, and has carried out studies in animal tumor models to evaluate therapeutic efficacy of nanodrugs including chemotherapeutic drugs, gene-silencing agents, and cancer vaccines. The leading compounds are currently undergoing cGMP production and GLP toxicity evaluation in preparation for human clinical trials.
He has published papers in Nature, Nature Genetics, Cell Reports, Journal of Clinical Investigation, Clinical Cancer Research, Clinical Chemistry, ACS Nano,Small, Biomaterials and other international journals.

https://scholars.houstonmethodist.org/en/persons/haifa-shen(4ea71a3c-3318-4ead-a385-df224e41b7ca).html